Pfiz­er's JAK1 chal­lenger to Dupix­ent shines in an­oth­er PhI­II, but safe­ty is­sues still cast a shad­ow

Pfiz­er is rack­ing up am­mu­ni­tion for its full-on as­sault against Re­gen­eron and Sanofi’s Dupix­ent fran­chise, with the lat­est topline win for an oral atopic der­mati­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER